1-kestose and Food-Hypersensitivity

Interventions targeting the gut microbiota for treating food allergy (FA) have been gaining much attention. Although several studies have examined the effects of probiotics, few have verified the effects of prebiotic intervention on FA in humans.. We conducted a preliminary open-label, parallel-group comparison trial in children diagnosed with severe cow's milk allergy (CMA) who were instructed to ingest baked milk (BM; bread or cookies) daily. The subjects either received or did not receive the prebiotic 1-kestose (kestose) daily for 6 months. CMA symptoms and the threshold dose for milk protein were evaluated by oral food challenge with heated milk or BM. Blood and fecal samples were also collected for investigations of the antigen-specific immunoglobulin (Ig) E levels and microbiota composition.. Kestose treatment significantly increased the threshold dose for milk protein, and decreased the milk- and casein-specific IgE levels in serum. In those treated with kestose, the abundance of Fusicatenibacter spp. significantly increased in the feces, and a significant inverse correlation was seen between the abundance of Fusicatenibacter spp. and the milk- and casein-specific IgE levels.. Kestose treatment induced some tolerance to milk protein via changes in the gut microbiota composition in children with FA.. A 6-month treatment with the prebiotic kestose increased the threshold dose for milk protein, and decreased the serum levels of milk- and casein-specific IgE in children diagnosed with cow's milk allergy. The kestose treatment increased the abundance of Fusicatenibacter spp. in the gut, which was inversely correlated with the antigen-specific IgE levels. This is the first study to demonstrate that a prebiotic intervention induced some tolerance to an allergen in children with food allergy.

Topics: Allergens; Animals; Caseins; Cattle; Child; Female; Food Hypersensitivity; Gastrointestinal Microbiome; Humans; Immunoglobulin E; Infant; Milk Hypersensitivity; Milk Proteins

Atopic dermatitis (AD) is recently increasing among populations, but the underlying mechanisms remain controversial. Interactions between the gut microbiota and mucosal immunity are considered to be a crucial etiology. Fructooligosaccharide (FOS), prebiotics have been reported as activators of the gut microbiota.. The aim of this study was to investigate the effects of kestose, the smallest FOS and FOS on atopic dermatitis in mice.. An AD mouse model was developed by (ovalbumin) epidermal sensitization using BALB/c mice. Kestose (1%, 5%, and 10%) or FOS (5%, positive control) was orally administered throughout the study.. In comparison with the values observed for the control AD mice, transepidermal water loss (TEWL), clinical score, and skin inflammation on histopathology were significantly decreased by the oral administration of kestose. Total IgE, thymic stromal lymphopoietin (TSLP) in skin, and IL-4 were also suppressed by this administration. In addition, the population of CD4. These findings suggest that kestose activates the gut immune system to induce the tolerance against allergic skin inflammations in AD.

Topics: Animals; CD4-Positive T-Lymphocytes; Dermatitis, Atopic; Disease Models, Animal; Epidermis; Female; Food Hypersensitivity; Gastrointestinal Microbiome; Humans; Immune Tolerance; Immunity, Mucosal; Intestinal Mucosa; Mice; Mice, Inbred BALB C; Ovalbumin; Trisaccharides